Loading...
•
Jun 30, 2021
Arrowhead Pharmaceuticals Q3 2021 Earnings Report
Arrowhead Pharmaceuticals reported financial results for the fiscal third quarter ended June 30, 2021.
Key Takeaways
Arrowhead Pharmaceuticals reported revenue of $45.891 million and a net loss of $29.924 million for the fiscal third quarter ended June 30, 2021.
Received Breakthrough Therapy designation from the U.S. Food and Drug Administration for ARO-AAT.
Presented additional positive interim 48-week liver biopsy results from the ongoing AROAAT2002 study.
Announced a global collaboration and license agreement with Horizon Therapeutics for ARO-XDH.
Earned a $10 million option exercise fee from Janssen Pharmaceuticals, Inc. for ARO-JNJ1.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
Forward Guidance
This report does not contain forward guidance.